Everyone knows someone touched by cancer. The groundbreaking research done at Memorial Sloan-Kettering is crucial to those with the disease and everyone who loves them.

One new research development is T cell engineering. A recent New York Times article extolled the potential of this technique, which uses the patient's own laboratory-enhanced immune cells and has already shown dramatic success in treating blood cancers. "Our goal is to create targeted immunotherapies that are both potent and safe," says Michel Sadelain, Director of Memorial Sloan-Kettering's Center for Cell Engineering.

For more than a century, MSKCC has set the standard in research and treatments that have revolutionized cancer care, and each advance brings new hope to patients around the world.

Sign this pledge now to show your support for the researchers, doctors, and nurses at MSKCC who bring us closer each day to a world without cancer.